每周CT成像引导的自适应放疗在III期非小细胞肺癌中的局部控制与毒性:LARTIA试验结果
LARTIA前瞻性研究纳入217例接受每周模拟CT的局部晚期NSCLC患者,其中50例因肿瘤缩小行重计划。中位随访20.5个月,急性3级及以上肺毒性和食管毒性分别为2%和4%,晚期分别为4%和2%;边缘复发6%,野内和野外局部失败分别为20%和4%。作者认为毒性降低和边缘失败率低使自适应方法成为未来随机研究的选项,最可能在前瞻性新辅助放化疗试验中确认其应用。
要点
- 50例患者因肿瘤缩小接受重计划,急性3级及以上肺毒性和食管毒性分别为2%和4%。
- 边缘复发率为6%,野内和野外局部失败分别为20%和4%。
- 作者认为自适应方法毒性降低且边缘失败率低,可作为未来随机研究的选项。
核心结论
- 毒性降低和记录到的低边缘失败率使自适应方法成为未来随机研究的现代选项。
- 确认其应用的最佳场景可能是在新辅助放化疗试验中。
研究设计与样本
- 前瞻性研究,局部晚期NSCLC患者接受同步放化疗,治疗期间每周行胸部CT模拟定位。
- 肿瘤缩小时重新勾画肿瘤体积并制定新治疗计划(重计划)。
- 从2012年至2014年本中心接受每周模拟CT的217例患者中选出50例进行重计划。
- 毒性采用放射治疗肿瘤学组/欧洲癌症研究与治疗组织量表评估。
- 失败模式分为野内(重计划计划靶区[PTV]内二维和/或代谢进展)、边缘(初始PTV内但被排除在重计划PTV外的复发)和野外(初始PTV外复发)。
主要发现
- 中位随访20.5个月。
- 急性3级及以上肺毒性和食管毒性分别见于2%和4%的病例。
- 晚期肺毒性和食管毒性分别见于4%和2%的病例。
- 边缘复发见于6%的患者。
- 野内局部失败见于20%的患者,野外局部失败见于4%的患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anatomical change of tumor during radiotherapy contributes to target missing. However, in the case of tumor shrinkage, adaptation of volume could result in an increased incidence of recurrence in the area of target reduction. This study aims to investigate the incidence of failure of the adaptive approach and, in particular, the risk for local recurrence in the area excluded after replanning. METHODS: In this prospective study, patients with locally advanced NSCLC treated with concomitant chemoradiation underwent weekly chest computed tomography simulation during treatment. In the case of tumor shrinkage, a new tumor volume was delineated and a new treatment plan outlined (replanning). Toxicity was evaluated with the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scale. Patterns of failures were classified as in field (dimensional and/or metabolic progression within the replanning planning target volume [PTV]), marginal (recurrence in initial the PTV excluded from the replanning PTV), and out of field (recurrence outside the initial PTV). RESULTS: Replanning was outlined in 50 patients selected from a total of 217 patients subjected to weekly simulation computed tomography in our center from 2012 to 2014. With a median follow-up of 20.5 months, acute grade 3 or higher pulmonary and esophageal toxicity were reported in 2% and 4% of cases and late toxicity in 4% and 2%, respectively. Marginal relapse was recorded in 6% of patients, and 20% and 4% of patients experienced in-field and out-of-field local failure, respectively. CONCLUSIONS: The reduced toxicity and the documented low rate of marginal failures make the adaptive approach a modern option for future randomized studies. The best scenario to confirm its application is probably in neoadjuvant chemoradiation trials.
引用
- Ramella S, Fiore M, Silipigni S, et al. Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC. J Thorac Oncol. 2017. PMID: 28428149. doi:10.1016/j.jtho.2017.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。